ENPP2 and colorectal carcinoma: Aim of this study is to evaluate the effectiveness in experimental preclinical models of the ATX inhibitor IOA-289 on tumor progression of different gastrointestinal malignancies including intrahepatic cholangiocarcinoma (iCCA), HCC, colorectal adenocarcinoma (CRC) and pancreatic cancer (PC).